Coloplast A/S Sets New Financial Ambitions for the Future
In a significant move, Coloplast A/S has announced its ambitious financial targets as part of the launch of its new strategic initiative, Impact4. This initiative aims for a remarkable organic revenue growth rate of 7-8% until the fiscal year 2029/30. Furthermore, the company is committed to achieving a growth in absolute EBIT that aligns or exceeds revenue growth during this period, alongside a Return on Invested Capital (ROIC) metric of over 20% by the fiscal year 2029/30.
Overview of the Impact4 Strategy
During the Capital Markets Day scheduled for September 2025, Coloplast will provide a detailed overview of Impact4, which is designed to drive the company’s performance over the next five years. This strategy focuses on substantially increasing shareholder value through key financial milestones and a dedication to sustainable growth.
Key Financial Targets
The strategic financial ambitions set by Coloplast include:
- Organic revenue growth projected at 7-8%, reflecting a compounded annual growth rate (CAGR) through to FY 2029/30.
- Absolute EBIT growth aligned with or exceeding the revenue growth.
- Aiming for a ROIC exceeding 20% by FY 2029/30, with steady improvements expected throughout the strategy period.
Strategic Assumptions Behind the Financial Goals
Coloplast’s new financial ambitions are built upon several key assumptions that drive their strategic planning:
- Market growth during this timeframe is anticipated to be between 4-5%.
- The company expects a stable macroeconomic climate with no significant changes in tariffs or trade restrictions.
- Consistent quality, supply chain reliability, and distribution of products are critical for maintaining operations.
- The impact of pricing strategies is expected to be neutral during this timeframe.
- Strategically, no substantial mergers and acquisitions (M&A) are projected, focusing instead on smaller bolt-on acquisitions.
Additional Financial Considerations
Coloplast has outlined further financial parameters to ensure clarity on their projected outcomes:
- The capital expenditure to sales ratio is forecasted at 4-5%, decreasing to approximately 4% as they move further into the Impact4 strategy.
- A tax rate around 22% is expected over the period.
- The net working capital to sales ratio is projected to improve to near 24%.
- By FY 2029/30, a net debt/EBITDA ratio is expected to drop to about 1.5x.
- The capital allocation policy remains consistent, targeting a dividend payout ratio of 60-80% of net profit.
Participating in the Capital Markets Day
Shareholders and interested parties can engage with the plenary session of the Capital Markets Day virtually, with details available through Coloplast’s website. Comprehensive resources and materials will be accessible during the event to enhance understanding of their future direction and initiatives.
Frequently Asked Questions
What is Coloplast's new financial ambition?
Coloplast aims for an organic revenue growth rate of 7-8% until FY 2029/30, with strong growth in EBIT and a ROIC exceeding 20%.
When will Coloplast present their detailed strategy?
Coloplast will present the Impact4 strategy during the Capital Markets Day scheduled for September 2025.
What key assumptions support Coloplast's financial targets?
Key assumptions include a stable macroeconomy, market growth of 4-5%, and reliable product supply and distribution.
How is Coloplast planning to allocate capital?
Coloplast intends to maintain a capital allocation policy that targets a dividend payout of 60-80% of net profit.
Where can I find more information about Coloplast?
Additional information and updates can be found on Coloplast’s official website.
